👩🔬 Behind the scenes at AOA Dx! 🔬 With Ovarian Cancer Awareness Month around the corner, we're so excited to share more with you soon. You'll learn more about the people making early detection a reality, what our days looks like, and more! Stay tuned 👏 Ft: Robert Law, Ph.D., Anna Milik Jeter, Alexander Fisher #ovariancancer #womenshealth #science #research #biotech #lifescience #cancer #denver #colorado
AOA Dx
Biotechnology Research
Denver, CO 7,104 followers
Revolutionizing early diagnosis of Ovarian Cancer
About us
AOA Dx is developing the next frontier in early-stage cancer detection for women through its pioneering work in glycolipids and proprietary biomarker technology. Our revolutionary tumor marker ganglioside platform, GlycoLocate™, is paving the way for life-saving early cancer detection. In a first of its kind, AOA Dx is developing AKRIVIS GD™, an early-stage liquid biopsy test for ovarian cancer, that has proven excellent sensitivity and specificity in a recent study. We foresee novel tumor biomarker gangliosides as the future for diagnosis, prognosis, monitoring, and eventually targeted therapies across multiple cancers. AOA Dx was co-founded by three experts and passionate advocates of women’s health, who have worked together at two previous diagnostic startups, that both resulted in successful exits upon commercialization. AOA Dx, a Y combinator and VC backed company, raised an oversubscribed Seed Round to accelerate development and clinical studies. Awards & Accelerators: 1. Y Combinator 2. MassChallenge 3. Springboard Enterprises 4. MassMedic Ignite 5. Inc Magazine Top 100 Female Founders 6. Women's Health Innovation Summit Award 7. Massachusetts Life Sciences Center MassNextGen Award 8. The Wave Summit's Emerging Women Founder in Bio Award 9. The Eddies Award 10. Bloomberg New Economy Catalyst www.aoadx.com
- Website
-
http://www.aoadx.com
External link for AOA Dx
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Denver, CO
- Type
- Privately Held
- Founded
- 2020
- Specialties
- Medical Devices, Diagnostics, Prognostics, Biotechnology, Sales, Commercialization, Regulatory, Licensing, Quality, FDA, IVD, CE IVDR, Ovarian Cancer, Women's Health, Cancer Diagnostics, and Liquid Biopsy
Locations
-
Primary
Denver, CO 80221, US
-
New York City, NY 10011, US
-
Cambridge, MA 02138, US
Employees at AOA Dx
-
Anthony Bajoras
Founder & Managing Director at CANCER FUND
-
Sharon Vosmek
CEO, Astia & Managing Partner, Astia Fund. Series A/B Investor, Board Member, Advisor, Speaker, fierce advocate for her portfolio
-
Alice Zheng
Principal at RH Capital | women's health expert | MD/MBA/MPH | ex-McKinsey
-
Abigail McElhinny
Experienced product development executive
Updates
-
On Women's Equality Day, we celebrate the progress women have made in the fight for equal rights. But true equality cannot be achieved without addressing the disparities in women's health. At AOA, we are focusing on developing the first early detection tool for ovarian cancer Despite being one of the deadliest gynecological cancers, ovarian cancer often goes undetected until it's too late. This is not just a medical issue, it's an equality issue. Access to early detection and innovative diagnostics is essential to giving women the best chance at survival. We must continue to push for advancements in women's health, from research and funding to awareness and access to care. 👏
-
Looking for your next career adventure 🔍 ? AOA Dx is seeking a Research Associate! This is an exciting opportunity to work with a dynamic start-up in Denver pioneering the field of glycolipids through the utilization of tumor marker gangliosides, the next class of biomarkers in early cancer detection 👏 ! The Research Associate is responsible for carrying out reagent and assay development activities in the laboratory, working to achieve development project goals including data analysis and assay qualification. This is a laboratory position performing a range of assays and methods from manual immunoassay and extraction methods to the use of HPLC or LC-MS instrumentation on a routine basis. Learn more here: https://lnkd.in/dmkDysBX #colorado #coloradojobs #biotech #lifescience #womenshealth #cancer #ovariancancer
-
-
What an amazing day to celebrate and advocate for women's health! Liz Powell brought together some of the most inspiring and influential leaders for "A New Era in Women's Health" forum in Chicago 👏!!! We had the chance to see many of our friends, partners, investors, advisors, and more. Certainly a day for the books! 🥳 cc: Oriana Papin-Zoghbi Ariel Kramer Naseem Sayani (she/her) Elizabeth Garner Crystal Pirtle Tyler PhD, MPH Dana Sun Shikha Jain, MD, FACP Bridgette René McCullough, PhD, MSL, Northwestern IRB Sally Wolf Melissa Bowley Nicole C. Woitowich
-
-
From Singapore to Denver, Colorado ✈️👏 This week, we were excited to welcome our investors from Adaptive Capital Partners! Thank you to Shi-Ying Lau 刘诗莹 and Rosalind Tan (陈燕晴) 陈燕晴 for making the journey. It was a pleasure having you with us. Cheers to a future of transforming women's health together! Ft: Emma Martin, Anna Milik Jeter, and Abigail McElhinny 💫
-
-
"Of the 1,741 patients who had their ovarian cancer test fast-tracked, 119 were diagnosed with high grade serous ovarian cancer, one of the more deadly variations of the disease. Over a quarter (25.2%) of patients included in the study had been diagnosed with stage one or two ovarian cancer, and of these women, 93% went on to survive for more than five years. But the survival rates for patients who were diagnosed with advanced ovarian cancer were only 13%."
Quarter of women with serous ovarian cancer could get earlier diagnosis – UK study
theguardian.com
-
Last week, the full AOA Clinical Ops team went to Nashville, TN for their in-person meeting with 17 site research staff that we work closely with on the OVERT Study! The meeting facilitated discussions on best practices for recruitment and enrollment. The clinical team put a tremendous amount of much work into this event and we are so grateful for their dedication and our sites' dedication! Ft: Anna Milik Jeter, Oriana Papin-Zoghbi, Elizabeth Yarber, Lindsey Kemp, Jeanne Jones, Savannah Harris, Cordia Simmons, Michael Matthews
-
-
"The first half of 2024 has brought positive momentum to women’s health: from President Biden’s Executive Order on Advancing Women’s Health Research and Innovation to Vice President Harris' support of women's reproductive health and safety, from the launch of a women’s health PAC to Melinda French Gates’ planned investment of $1B in women, including their health." Some key highlights: ✅ Increased VC Funding: Women’s health companies received $679.48M in venture capital funding in the first half of 2024, a 3% increase from the previous high in mid-2022. ✅Rising Average Deal Size: The average deal size for women’s health companies has reached a new high of $12.58M in the first half of 2024. ✅Growing Number of Large Deals: The number of women’s health companies raising over $50M in a single round has increased, with at least four companies achieving this in the first half of 2024. ✅Stable Percentage of Total VC Funding: Women’s health has maintained a steady share of overall VC funding in healthcare, receiving about 2.5% in the first half of 2024, slightly above the historical average. Interesting and informative read by Eva Epker! Check out the full article here:
The State Of Investments In Women’s Health, Halfway Through 2024
social-www.forbes.com
-
Thank you Dr. Elizabeth Garner for your invaluable support!
-